Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Total Debt (2019 - 2025)

Puma Biotechnology's Total Debt history spans 7 years, with the latest figure at $22.5 million for Q4 2025.

  • For Q4 2025, Total Debt fell 66.41% year-over-year to $22.5 million; the TTM value through Dec 2025 reached $22.5 million, down 66.41%, while the annual FY2025 figure was $22.5 million, 66.41% down from the prior year.
  • Total Debt reached $22.5 million in Q4 2025 per PBYI's latest filing, down from $33.7 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $100.1 million in Q2 2021 to a low of $22.5 million in Q4 2025.
  • Average Total Debt over 5 years is $83.6 million, with a median of $97.5 million recorded in 2022.
  • Peak YoY movement for Total Debt: surged 600.93% in 2021, then tumbled 66.41% in 2025.
  • A 5-year view of Total Debt shows it stood at $97.1 million in 2021, then increased by 1.25% to $98.3 million in 2022, then increased by 1.37% to $99.7 million in 2023, then crashed by 32.72% to $67.0 million in 2024, then crashed by 66.41% to $22.5 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Total Debt are $22.5 million (Q4 2025), $33.7 million (Q3 2025), and $44.9 million (Q2 2025).